SynthesisDrug safety2014
Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies.
Synthesis in Drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.The international journal of neuropsychopharmacology · 2020Pooled it
- Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis.BMC psychiatry · 2019Pooled it
- Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis.British journal of clinical pharmacology · 2016Pooled it
- Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies.Drug safety · 2014Pooled it
- Hyperhomocysteinemia is associated with the risk of venous thromboembolism in patients with mental illness: a case-control study.Frontiers in psychiatry · 2024Article
- The Risk of Venous Thromboembolism Events Resulting in Hospitalization following Exposure to Antipsychotic Medication in Pre-Disposed Adult Patients.Innovations in pharmacy · 2024Article
- The risk of hospitalization for psychotic disorders following hospitalization for COVID-19: a French nationwide longitudinal study.Molecular psychiatry · 2023Article
- Recognition of Strokes in the ICU: A Narrative Review.Journal of cardiovascular development and disease · 2023Review
- Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications.Therapeutic advances in psychopharmacology · 2023Article
- Antipsychotic drugs may contribute to venous thromboembolism - a case report and review literature.JRSM open · 2023Article
- The development and validation of a medicines optimisation tool to protect the physical health of people with severe mental illness (OPTIMISE).BMC psychiatry · 2022Review
- COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis.Frontiers in psychiatry · 2021Article
- Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode.Neuropsychiatric disease and treatment · 2021Article
- Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies.Therapeutic advances in psychopharmacology · 2021Article
- The Usefulness of the Combination of D-Dimer and Soluble Fibrin Monomer Complex for Diagnosis of Venous Thromboembolism in Psychiatric Practice: A Prospective Study.Vascular health and risk management · 2021Article
- Acute Pulmonary Embolism Associated with Low-Dose Olanzapine in a Patient without Risk Factors for Venous Thromboembolism.Case reports in vascular medicine · 2021Article
- Two pulmonary emboli in a psych pod.Journal of the American College of Emergency Physicians open · 2020Article
- COVID-19, hypercoagulation and what it could mean for patients with psychotic disorders.Brain, behavior, and immunity · 2020Review
- Death Associated With Coronavirus (COVID-19) Infection in Individuals With Severe Mental Disorders in Sweden During the Early Months of the Outbreak-An Exploratory Cross-Sectional Analysis of a Population-Based Register Study.Frontiers in psychiatry · 2020Article
- Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series.Frontiers in psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a serious disorder that may be complicated by pulmonary embolism (PE). Case reports and observational studies published in the early 1950s suggested that antipsychotic (AP) drugs may represent a risk factor, while observational studies conducted in the last 3 decades have provided conflicting results.
objectiveThe aim was to investigate whether AP drugs increase the risk of VTE and PE, and to ascertain the risk associated with first- and second-generation AP drugs and with exposure to individual drugs. DATA SOURCE: Relevant studies were located by searching MEDLINE, PubMed, EMBASE, PsychINFO, CINAHL and Scopus up to March 2013. Reference lists of relevant papers and previous review articles were hand searched for other relevant studies. STUDY SELECTION: Based on the titles and abstracts of 1,386 citations, we identified 30 potentially relevant studies. Of these, 17 studies were eligible for inclusion and were included in the meta-analysis. MAIN OUTCOMES AND MEASURES: The primary outcome measure of this meta-analysis was the occurrence of VTE or PE in individuals exposed to AP drugs in comparison with individuals unexposed or with past exposure to AP drugs.
resultsAntipsychotic exposure was associated with a significant increase in risk of developing VTE [odds ratio (OR) 1.54, 95% confidence interval (CI) 1.28-1.86, 11 studies]. Exposure to APs did not significantly increase the risk of PE (OR 4.90, 95% CI 0.77-30.98, three studies), but the overall estimate was highly heterogeneous and the CI included the possibility of substantial harm. Random-effects meta-analysis on the risk of VTE associated with exposure to first- (OR 1.74, 95% CI 1.28-2.37, six studies) and second-generation (OR 2.07, 95% CI 1.74-2.52, five studies) APs revealed an increased risk. Only a few studies provided data on individual drugs, and estimates of effect were very uncertain.
conclusionsAntipsychotic exposure in unselected patient populations may be associated with a 50% increase in the risk of developing VTE. However, between-study heterogeneity limits the confidence in this estimate. This increased risk similarly applies to first- and second-generation AP drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.